China Biologic Products Hosts its First Forum for Strategy and Development
July 16 2009 - 8:00AM
PR Newswire (US)
TAIAN CITY, China, July 16 /PRNewswire-Asia-FirstCall/ -- China
Biologic Products, Inc. (OTC:CBPO) (BULLETIN BOARD: CBPO) ("China
Biologic" or the "Company"), one of the leading plasma-based
pharmaceutical companies in the People's Republic of China ("PRC"),
today announced that the Company hosted a forum of industry experts
on July 10 - 11, 2009, at its headquarters in Tai'an, Shandong
Province, to discuss future development strategies for the Company.
Experts from the bio-pharmaceutical industry included Mr. Zhongwei
Zheng, head of the research and development center at the Institute
of Blood Transfusion at the Chinese Academy of Medical Science, and
Mr. Fengshan Wang, Dean of School of Pharmaceutical Sciences at the
Shandong University. Messrs. Zheng and Wang and other domestic and
international academics and experts, gathered together to discuss
strategies for the development of the new China Biologic, which
recently became the largest non-state-owned plasma-based
pharmaceutical Company in China following the Company's
acquisitions of Dalin Biologic Technologies and also its equity
investment in Xi'an Huitian Blood Products. The forum provided a
platform for industry experts to discuss and provide advice to the
Company that could create synergies among its subsidiaries
including, the initiation of research and development of new drugs,
efficient use of resources among the subsidiaries, quality control
procedures during collection, production and distribution
processes, and other expert opinions to create long term,
sustainable growth for the Company. "The forum has provided us with
many strategic ideas to further the growth of the new China
Biologic," said Mr. Chao Ming Zhao, CEO of China Biologic Products.
"We look forward to implementing some of those strategies and
create synergies among our subsidiaries." About China Biologic
Products, Inc. China Biologic Products, Inc. (the "Company"),
through its indirect majority-owned subsidiaries, Shandong Taibang
Biological Products Co. Ltd. and Chongqing Dalin Biologic
Technologies Co., Ltd, and its equity investment in Xi'an Huitian
Blood Products Co., Ltd., is currently the largest non-state-owned
plasma-based biopharmaceutical company approved by the Chinese
government. The Company is a fully integrated biologic products
company with plasma collection, production and manufacturing,
research and development, and commercial operations. The Company's
blood products are irreplaceable during medical emergencies, and
are used for the prevention and treatment of various diseases. It
sells its plasma-based biopharmaceutical products to hospitals and
other healthcare facilities in China. Safe Harbor Statement This
release may contain certain "forward-looking statements" relating
to the business of China Biologic Products, Inc. and its subsidiary
companies. All statements, other than statements of historical fact
included herein are "forward-looking statements," including
statements regarding: the impact of the Company's forum for
strategy and development on the business and operations of the
Company, including the ability of the Company to create synergies
among its subsidiaries; the ability of the Company to achieve its
commercial objectives; the business strategy, plans and objectives
of the Company and its subsidiaries; and any other statements of
non-historical information. These forward-looking statements are
often identified by the use of forward-looking terminology such as
"believes," "expects" or similar expressions, involve known and
unknown risks and uncertainties. Although the Company believes that
the expectations reflected in these forward-looking statements are
reasonable, they do involve assumptions, risks and uncertainties,
and these expectations may prove to be incorrect. Investors should
not place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. The Company's
actual results could differ materially from those anticipated in
these forward-looking statements as a result of a variety of
factors, including those discussed in the Company's periodic
reports that are filed with the Securities and Exchange Commission
and available on its website (http://www.sec.gov/). All forward-
looking statements attributable to the Company or persons acting on
its behalf are expressly qualified in their entirety by these
factors. Other than as required under the securities laws, the
Company does not assume a duty to update these forward-looking
statements. For more information, please contact: Company Contact:
Mr. Y. Tristan Kuo Chief Financial Officer China Biologic Products,
Inc. Tel: +86-538-6202206 Email: Web: http://www.chinabiologic.com/
Investor Relations Contact: Mr. Crocker Coulson, President CCG
Investor Relations Tel: +1-646-213-1915 (NY office) or Mr. Gary
Chin Tel: +1-646-213-1909 Email: Web: http://www.ccgirasia.com/
DATASOURCE: China Biologic Products, Inc. CONTACT: Company Contact:
Mr. Y. Tristan Kuo, Chief Financial Officer Of China Biologic
Products, Inc., +86-538-6202206, or ; Or Investor Relations
Contact: Mr. Crocker Coulson, President of CCG Investor Relations,
+1-646-213-1915 (NY office) or Mr. Gary Chin, +1-646-213-1909, or
Web site: http://www.chinabiologic.com/ http://www.ccgirasia.com/
Copyright